De Felice Francesca, Musio Daniela, Bulzonetti Nadia, Raffetto Nicola, Tombolini Vincenzo
Cattedra di Radioterapia, Dipartimento di Scienze Radiologiche Oncologiche e Anatomo-Patologiche, "Sapienza" University of Rome, Rome, Italy.
Cattedra di Radioterapia, Dipartimento di Scienze Radiologiche Oncologiche e Anatomo-Patologiche, "Sapienza" University of Rome, Rome, Italy ; Fondazione Spencer-Lorillard, Rome, Italy.
J Clin Med Res. 2014 Dec;6(6):409-13. doi: 10.14740/jocmr1908w. Epub 2014 Sep 9.
Systemic neo-adjuvant therapy plays a primary role in the management of locally advanced breast cancer. Without having any negative effect in overall survival, induction chemotherapy potentially assures a surgery approach in unresectable disease or a conservative treatment in technically resectable disease and acts on a well-vascularized tumor bed, without the modifications induced by surgery. A specific issue has a central function in the neo-adjuvant setting: lymph nodes status. It still represents one of the strongest predictors of long-term prognosis in breast cancer. The discussion of regional radiation therapy should be a matter of debate, especially in a pathological complete response. Currently, the indication for radiotherapy is based on the clinical stage before the surgery, even for the irradiation of the loco-regional lymph nodes. Regardless of pathological down-staging, radiation therapy is accepted as standard adjuvant treatment in locally advanced breast cancer.
全身新辅助治疗在局部晚期乳腺癌的管理中起着主要作用。诱导化疗在不影响总生存期的情况下,有可能确保对不可切除疾病采取手术方法,或对技术上可切除疾病采取保守治疗,并作用于血管丰富的肿瘤床,而不会受到手术引起的改变。一个特定问题在新辅助治疗环境中具有核心作用:淋巴结状态。它仍然是乳腺癌长期预后最强的预测指标之一。关于区域放射治疗的讨论应该是一个有争议的问题,特别是在病理完全缓解的情况下。目前,放射治疗的指征是基于手术前的临床分期,即使是对局部区域淋巴结进行照射。无论病理降期如何,放射治疗在局部晚期乳腺癌中被接受为标准辅助治疗。